Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome

This cohort study defines the distinguishing features of progressive supranuclear palsy and corticobasal syndrome and assesses their usefulness in facilitating early diagnosis and separation from Parkinson disease among patients with atypical parkinsonian syndromes.

[1]  W. Oertel,et al.  How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy , 2019, Movement disorders : official journal of the Movement Disorder Society.

[2]  Nikolaus R. McFarland,et al.  Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial , 2019, The Lancet Neurology.

[3]  J. Rowe,et al.  Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration , 2019, bioRxiv.

[4]  M. T. Pellecchia,et al.  Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy , 2018, Journal of Neurology.

[5]  J. Hardy,et al.  Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype , 2018, bioRxiv.

[6]  Sonja W. Scholz,et al.  NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases , 2017, Neurobiology of Aging.

[7]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[8]  K. Blennow,et al.  Blood-based NfL , 2017, Neurology.

[9]  Richard J. Binney,et al.  Progression of brain atrophy in PSP and CBS over 6 months and 1 year , 2016, Neurology.

[10]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[11]  J. Rowe,et al.  Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes , 2016, Neurology.

[12]  K. Blennow,et al.  Plasma neurofilament light chain predicts progression in progressive supranuclear palsy , 2016, Annals of clinical and translational neurology.

[13]  R. Barker,et al.  Tracking Parkinson’s: Study Design and Baseline Patient Data , 2015, Journal of Parkinson's disease.

[14]  David Kulp,et al.  A guide to genome‐wide association analysis and post‐analytic interrogation , 2015, Statistics in medicine.

[15]  Norbert Schuff,et al.  Bayesian segmentation of brainstem structures in MRI , 2015, NeuroImage.

[16]  Veronica Redaelli,et al.  Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis , 2015, The Lancet Neurology.

[17]  J. Beilby,et al.  Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer's disease. , 2014, American journal of neurodegenerative disease.

[18]  E. Tolosa,et al.  The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases , 2014, Movement disorders : official journal of the Movement Disorder Society.

[19]  J. Long,et al.  Illumina human exome genotyping array clustering and quality control , 2014, Nature Protocols.

[20]  Clifford R Jack,et al.  Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial , 2014, The Lancet Neurology.

[21]  E. Tolosa,et al.  A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy , 2014, Movement disorders : official journal of the Movement Disorder Society.

[22]  Elaine Niven,et al.  Screening for cognition and behaviour changes in ALS , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[23]  J. Hodges,et al.  Edinburgh Research Explorer Validation of the New Consensus Criteria for the Diagnosis of Corticobasal Degeneration , 2022 .

[24]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[25]  B. Borroni,et al.  CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  D. Dickson,et al.  Neuropathology of variants of progressive supranuclear palsy. , 2010, Current opinion in neurology.

[27]  A. Lees,et al.  Does corticobasal degeneration exist? A clinicopathological re-evaluation. , 2010, Brain : a journal of neurology.

[28]  David R Williams,et al.  Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges , 2009, The Lancet Neurology.

[29]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[30]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[31]  L. Golbe,et al.  A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.

[32]  John R Hodges,et al.  The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.

[33]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[34]  Sid Gilman,et al.  Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) , 2004, Movement disorders : official journal of the Movement Disorder Society.

[35]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[36]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[37]  Andrew J. Lees,et al.  Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.

[38]  D. Burn,et al.  The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. , 2001, Brain : a journal of neurology.

[39]  G. Filippini,et al.  Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy , 2001, Neurological Sciences.

[40]  Y Ben-Shlomo,et al.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study , 1999, The Lancet.

[41]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[42]  J. Olszewski,et al.  Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 1964 .

[43]  Children L. Schlaggar.  Movement Disorders in , 2003 .

[44]  Z. Schwab,et al.  Projection technique for evaluating surgery in Parkinson’s disease , 1969 .